BioNTech SE has announced its all-stock acquisition of CureVac, marking a significant step in its strategic expansion in the field of mRNA-based cancer immunotherapy. The transaction, approved by both companies' management and supervisory boards, aims to enhance BioNTech's research, development, manufacturing, and commercialization capabilities. By integrating CureVac's research and manufacturing site in Tübingen, BioNTech seeks to leverage complementary scientific capabilities and proprietary technologies to accelerate the development of transformative mRNA-based medicines. The acquisition is expected to close in 2025, subject to customary closing conditions and regulatory approvals.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。